{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Xu MQ"],"funding":["Major New Drug Innovation and Development Program of China","National Natural Science Foundation of China","Innovation Team of the Ministry of Education","National Key Research and Development Program of China"],"pagination":["1603-1615"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8330778"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["28(1)"],"pubmed_abstract":["Small molecule-chemotherapeutic drug conjugate nanoparticles (SMCDC NPs) has a great advantage in improving drug loading. However, the factors which influence these conjugates forming stable nanoparticles (NPs) are currently unclear. In our previous studies, we synthesized a series of fatty acid-paclitaxel conjugates and suggested that the changes in the hydrophobic parameters (XlogP), solubility parameters and crystallinity of these fatty acid-paclitaxel conjugates were the key factors for affecting these small molecule-chemotherapeutic drug conjugates (SMCDCs) forming stable NPs in water. Here, we selected clinically widely used chemotherapeutic drug (docetaxel (DTX), doxorubicin (DOX) and irinotecan (Ir)) as model drug, and chose three straight-chain fatty acids (acetic acid (Ac), hexan"],"journal":["Drug delivery"],"pubmed_title":["Effect of XlogP and hansen solubility parameters on the prediction of small molecule modified docetaxel, doxorubicin and irinotecan conjugates forming stable nanoparticles."],"pmcid":["PMC8330778"],"funding_grant_id":["2017YFA0205600","2018ZX09721003-004","81573360","BMU2017TD003"],"pubmed_authors":["Li H","Wang JR","Zhong T","Zhang X","Xu MQ","Yao X","Li ZY","Feng ZH"],"additional_accession":[]},"is_claimable":false,"name":"Effect of XlogP and hansen solubility parameters on the prediction of small molecule modified docetaxel, doxorubicin and irinotecan conjugates forming stable nanoparticles.","description":"Small molecule-chemotherapeutic drug conjugate nanoparticles (SMCDC NPs) has a great advantage in improving drug loading. However, the factors which influence these conjugates forming stable nanoparticles (NPs) are currently unclear. In our previous studies, we synthesized a series of fatty acid-paclitaxel conjugates and suggested that the changes in the hydrophobic parameters (XlogP), solubility parameters and crystallinity of these fatty acid-paclitaxel conjugates were the key factors for affecting these small molecule-chemotherapeutic drug conjugates (SMCDCs) forming stable NPs in water. Here, we selected clinically widely used chemotherapeutic drug (docetaxel (DTX), doxorubicin (DOX) and irinotecan (Ir)) as model drug, and chose three straight-chain fatty acids (acetic acid (Ac), hexan","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Dec","modification":"2025-06-01T03:26:29.087Z","creation":"2022-02-11T05:35:22.98Z"},"accession":"S-EPMC8330778","cross_references":{"pubmed":["34319209"],"doi":["10.1080/10717544.2021.1958107"]}}